A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
| Image |  |
|---|---|
| Description | scientific article published on 13 September 2017 |
| Author/s |
author: Hajime Asahina |
| Publication date | September 13, 2017 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |